Rigel ‘Fosta’ Child in Spotlight After R333 Fails Phase II
With Rigel Pharmaceuticals Inc.’s R333 kaput in Phase II trials for skin lesions in discoid lupus erythematosus patients, attention has turned from the topical JAK/SYK inhibitor to fostamatinib, an oral SYK inhibitor bound for Phase III trials in the first half of next year in immune thrombocytopenic purpura (ITP).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST